Device Trial Radar · NCT06175611
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
Last checked: Nov 20, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Dec 10, 2023
Primary completion
Apr 2024
Study completion Apr 2024
Sponsor
- Lead sponsor
- EDAN Instruments Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 19, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and 2. ClariLight Influenza A/B \& RSV test kits, for the qualitative detection and differential diagnosis of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) present in anterior nasal and oropharyngeal swab, in combination with an automated molecular diagnostic analyzer and sample collection tube by comparing them against a CE marked, in-vitro diagnostic device, used in the standard of care.
Conditions
- SARS-CoV2 Infection
- Influenza A
- Influenza B
- Respiratory Syncytial Virus (RSV)
Interventions
COVID-19/Flu A/Flu B/RSV Test KitDevice
The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection. Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care. This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Percentage Agreement (PPA)Time frame: Day 1. No follow-up is required for this study.
- Negative Percentage Agreement (NPA).Time frame: Day 1. No follow-up is required for this study.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hospital General Universitario Dr. Balmis de Alicante
Alicante, Spain · Recruiting
Laboratorio Central Health Diagnostics Quirónsalud
Madrid, Spain · Not yet recruiting
Hospital Universitario de Getafe
Madrid, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.